99 related articles for article (PubMed ID: 6104700)
1. Effects of 3,4-dihydroxyphenylpyruvic acid and L-glutamic acid on some pharmacokinetic parameters of L-dopa in the rat.
Lindén IB
J Pharm Pharmacol; 1980 May; 32(5):344-8. PubMed ID: 6104700
[TBL] [Abstract][Full Text] [Related]
2. The effect of simultaneous administration of 3,4-dihydroxyphenylpyruvic acid and L-dopa on the bioavailability of L-dopa in rat and mouse.
Hietala P; Lindén IB; Grönfors N
J Pharm Pharmacol; 1979 Apr; 31(4):205-8. PubMed ID: 36456
[TBL] [Abstract][Full Text] [Related]
3. Transamination and other metabolic pathways of 3,4-dihydroxyphenylpyruvic acid in rats when simultaneously administered with L-dopa.
Lindén IB; Karlsson M; Niemi S; Penttilä A
J Pharm Pharmacol; 1982 Nov; 34(11):719-23. PubMed ID: 6129302
[TBL] [Abstract][Full Text] [Related]
4. Effects of 3,4-dihydroxyphenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase.
Lindén IB; Neuvonen PJ; Vapaatalo H
Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):266-9. PubMed ID: 7136732
[TBL] [Abstract][Full Text] [Related]
5. Effect of 3,4-dihydroxyphenylpyruvic acid on the metabolism of L-DOPA in isolated perfused rat liver.
Lindén IB; Niemi S
Acta Pharmacol Toxicol (Copenh); 1982 Nov; 51(5):434-40. PubMed ID: 7164823
[TBL] [Abstract][Full Text] [Related]
6. Elevated striatal dopamine levels following administration of D-DOPA and its alpha-keto acid metabolite DHPPA: behavioral and physiological studies in vivo in the rat.
Brannan T; Prikhojan A; Yahr MD
Brain Res; 1996 Apr; 718(1-2):165-8. PubMed ID: 8773780
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
8. D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in rats.
Karoum F; Freed WJ; Chuang LW; Cannon-Spoor E; Wyatt RJ; Costa E
Brain Res; 1988 Feb; 440(1):190-4. PubMed ID: 3129126
[TBL] [Abstract][Full Text] [Related]
9. Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity.
Dolphin A; Jenner P; Marsden CD
Pharmacol Biochem Behav; 1976 Oct; 5(4):431-9. PubMed ID: 1005491
[TBL] [Abstract][Full Text] [Related]
10. Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian rat.
Moses J; Siddiqui A; Silverman PB
Neurosci Lett; 1996 Nov; 218(3):145-8. PubMed ID: 8945749
[TBL] [Abstract][Full Text] [Related]
11. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
Rose S; Jenner P; Marsden CD
Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
[TBL] [Abstract][Full Text] [Related]
12. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
13. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
Gołembiowska K; Dziubina A
Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
[TBL] [Abstract][Full Text] [Related]
14. Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment.
Rose S; Jenner P; Marsden CD
J Pharm Pharmacol; 1991 May; 43(5):325-30. PubMed ID: 1680174
[TBL] [Abstract][Full Text] [Related]
15. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
Lindén IB; Nissinen E; Etemadzadeh E; Kaakkola S; Männistö P; Pohto P
J Pharmacol Exp Ther; 1988 Oct; 247(1):289-93. PubMed ID: 3171977
[TBL] [Abstract][Full Text] [Related]
16. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
[TBL] [Abstract][Full Text] [Related]
17. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
Brannan T; Martínez-Tica J; Yahr MD
Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
[TBL] [Abstract][Full Text] [Related]
18. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
Napolitano A; Zürcher G; Da Prada M
Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
[TBL] [Abstract][Full Text] [Related]
19. The role of 3-O-methyldopa in the side effects of L-dopa.
Lee ES; Chen H; King J; Charlton C
Neurochem Res; 2008 Mar; 33(3):401-11. PubMed ID: 17713853
[TBL] [Abstract][Full Text] [Related]
20. Different effects of harmine on plasma concentrations of L-dopa and on cerebral dopamine metabolism in rabbits and rats.
Meneguz A; Betto P; Ricciarello G
Pharmacology; 1994 Jun; 48(6):360-6. PubMed ID: 8047555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]